Zobrazeno 1 - 10
of 22
pro vyhledávání: '"эплеренон"'
Publikováno v:
Бюллетень сибирской медицины, Vol 20, Iss 2, Pp 29-35 (2021)
Aim. To study the effect of eplerenone on the activity of free radical oxidation and renal function in rats with experimental diabetes mellitus induced by streptozotocin.Materials and methods. Experiments were carried out on 36 male Wistar rats. Diab
Externí odkaz:
https://doaj.org/article/34279101ce7046e9820ddeeeab38716e
Autor:
O. A. Osipova, V. P. Mikhin, A. I. Golovin, O. N. Belousova, D. N. Perutsky, P. K. Alferov, S. L. Konstantinov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 6 (2022)
Aim. To conduct a comparative analysis of the effect of long-term pharmacotherapy (12 months) using a β-blocker (nebivolol) and its combination with eplerenone in patients after ST-segment elevation acute coronary syndrome (STE-ACS) with heart failu
Externí odkaz:
https://doaj.org/article/782b1235fc014ebcbf8bbccb7ccc4edc
Publikováno v:
Архивъ внутренней медицины, Vol 9, Iss 4, Pp 260-268 (2019)
Atrial fibrillation (AF) is one of the most common cardiac rhythm disorders. Its prevalence is about 1 % in the general population and exceeds 7 % in individuals older than 60 years of age. It is known that hyperactivation of the renin-angiotensin-al
Externí odkaz:
https://doaj.org/article/ed10706ed1e54ce5ac1d3556095fecbf
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 46-51 (2015)
Chronic heart failure (CHF) today is a heart condition with the least favourable prognosis. Over the past 10-15 years, in addition to strong rationale supporting the effectiveness of angiotensin-converting enzyme inhibitors (ACEI), results of use wer
Externí odkaz:
https://doaj.org/article/66d27e7b6a5d4616936184c42e05d1db
Autor:
Князькова, I. I.
Publikováno v:
Лекарства Украины; № 7(263) (2022); 36-40
Medicine of Ukraine; No. 7(263) (2022); 36-40
Ліки України; № 7(263) (2022); 36-40
Medicine of Ukraine; No. 7(263) (2022); 36-40
Ліки України; № 7(263) (2022); 36-40
The aim of the work is to study the dynamics of diastolic function parameters, the content of the soluble growth factor receptor expressed by gene 2 (sST2) and the N-terminal fragment of brain natriuretic propeptide (NT-proBNP) in the blood of patien
Autor:
R. Eschalier, J.J.V. McMurray, K. Swedberg, D.J. Veldhuisen van, H. Krum, S.J. Pocock, H. Shi, J. Vincent, P. Rossignol, F. Zannad, B. Pitt
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 10, Iss 1, Pp 106-115 (2015)
Translation articles:R. Eschalier, J.J.V. McMurray, K. Swedberg, D.J. van Veldhuisen, H. Krum, S.J. Pocock, H. Shi, J. Vincent, P. Rossignol, F. Zannad, B. Pitt, for the EMPHASIS-HF Investigators “Safety and Efficacy of Eplerenone in Patients at Hi
Externí odkaz:
https://doaj.org/article/64a04579dfce4aa6a0df5926d041b17f
Autor:
B. B. Gegenava, O. M. Drapkina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 177-181 (2015)
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
Externí odkaz:
https://doaj.org/article/268161b4011246c1aec0ca2b694195c2
Autor:
Yu. M. Lopatin, E. Yu. Lopatina
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 14, Iss 4, Pp 86-91 (2015)
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this t
Externí odkaz:
https://doaj.org/article/5da45cd8ec0c4dcca77773c187012a7e
Autor:
MG Bubnova
Publikováno v:
Медицинский совет, Vol 0, Iss 12, Pp 70-80 (2014)
The review of literature discusses pathogenetic aspects of chronic heart failure and post-infarction remodelling in the heart. The focus is on the role of neurohormonal activation and the important role of aldosterone. There is data on the efficacy a
Externí odkaz:
https://doaj.org/article/03b2820fe788499d91b086eadcddfc0f
Publikováno v:
Ожирение и метаболизм, Vol 9, Iss 4, Pp 3-9 (2012)
Primary hyperaldosteronism (PHA) is a clinical syndrome that develops as a result of excess production of aldosterone by adrenal glomerular zone, where aldosterone secretion is completely or partially autonomous in relation to the renin-angiotensin s
Externí odkaz:
https://doaj.org/article/f9a85c365d854c38b6e1dd753cf57cb9